Despite major strides in antiretroviral therapy (ART), the human immunodeficiency virus (HIV) market still faces serious challenges that threaten long-term control of the disease.

The most pressing issue is the lack of affordable access to newer therapies, which - despite offering better adherence and fewer side effects - remain out of reach.

For many patients due to high costs and limited insurance coverage, according to  pharma analytics company GlobalData.

GlobalData’s report, "Human Immunodeficiency Virus (HIV): Seven-Market (7M) Drug Forecast and Market Analysis to 2033.

Reveals that unmet needs including underfunding of prevention programs, poor mental health integration, adherence challenges and affordability barriers remain the key obstacles in achieving HIV control and reducing transmission.

This article is accessible to registered users, to continue reading please register for free.  

A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. 

If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Source: Thepharmaletter